Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Convalescent Methylene Blue Treated (MBT) Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients: a Randomized Double Blind Study (COnV-ert)

NCT04621123 is registered in ClinicalTrials.gov with Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia as lead sponsor.

NCT NCT04621123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04621123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Convalescent Methylene Blue Treated (MBT) Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients: a Randomized Double Blind Study (COnV-ert)
Lead sponsor
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Phase
Phase 2
Overall status
Completed
Start date
November 10, 2020
Completion date
July 28, 2021
Enrollment
384 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

safety and efficacy, sars-cov-2 infection